Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 20 de 34
Filtrar
Más filtros

Base de datos
País/Región como asunto
Tipo del documento
Intervalo de año de publicación
1.
Curr Radiopharm ; 15(1): 32-39, 2022.
Artículo en Inglés | MEDLINE | ID: mdl-33397277

RESUMEN

BACKGROUND: Nimotuzumab is a humanized anti-epidermal growth factor receptor (EGFR) monoclonal antibody, nowadays used for tumour immunochemotherapy. This study aimed to label the conjugate DOTA-nimotuzumab with yttrium-90, in order to provide a ß- emitting radioimmunoconjugate (90Y-DOTA-nimotuzumab) potentially useful to assess the feasibility of a new radio-guided surgery approach. METHODS: The synthesis of 90Y-DOTA-nimotuzumab was performed in two days. Nimotuzumab was conjugated with a 50-fold excess of DOTA and then labelled with 90Y3+. The 90Y-DOTA-nimotuzumab preparation was optimized considering several parameters such as pH, temperature and reaction volume. Moreover, the 90Y-DOTA-nimotuzumab stability was evaluated in human plasma. RESULTS: The radioimmunoconjugate 90Y-DOTA-nimotuzumab was obtained with a radiochemical purity greater than 96%, and showed a good stability at 20°C as well as at 37°C in human plasma. CONCLUSIONS: The optimized conditions for a mild and easy preparation of 90Y-DOTA-nimotuzumab joined to a promising stability under physiological conditions suggest to propose this radioimmunoconjugate as a potential diagnostic radiopharmaceutical for ß- radio-guided surgery.


Asunto(s)
Antineoplásicos , Inmunoconjugados , Anticuerpos Monoclonales , Anticuerpos Monoclonales Humanizados , Compuestos Heterocíclicos , Humanos , Inmunoconjugados/farmacología , Compuestos Organometálicos , Radiofármacos/farmacología , Radioisótopos de Itrio/uso terapéutico
2.
Sci Rep ; 10(1): 4633, 2020 Mar 10.
Artículo en Inglés | MEDLINE | ID: mdl-32157105

RESUMEN

An amendment to this paper has been published and can be accessed via a link at the top of the paper.

3.
Sci Rep ; 9(1): 5623, 2019 04 04.
Artículo en Inglés | MEDLINE | ID: mdl-30948744

RESUMEN

This paper describes a new nuclear imaging agent, 2-(4-isothiocyanatobenzyl)-1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid of human albumin (HAC), potentially suitable for application in the Radio-guided Occult Lesion Localization (ROLL) of non-palpable mammalian cancerous lesions, as a tool to overtake the short radio-signal half-life of the technetium-99m based radiopharmaceutical currently used. This conjugate is a microsized powder aggregate, water-insoluble between pH 3 and 8.5, obtained by conjugating the protein with the macrocyclic chelating agent DOTA through a one-pot reaction in aqueous medium. The product has been fully characterized and is stable to the thermal conditions adopted for labeling; after radiolabeling with longer half-life radionuclides such as 177Lu or 111In, it has shown radiochemical purity (RCP) >90% and resulted stable when stored in saline or plasma for 6 days at 37 °C. A µPET/CT study, performed in vivo on adult female rats, showed that the radioactivity of HAC labeled with 64Cu remained located in the mammary glands for at least 40 h, without diffusion or drainage in healthy tissues or in the lymphatic circulation. This new imaging agent might make the ROLL procedure more accessible, safe and flexible, promoting a significant time and cost reduction of this intervention. Moreover, HAC might also be used in other radio-guided surgical procedures in oncology.


Asunto(s)
Neoplasias de la Mama/diagnóstico por imagen , Compuestos Heterocíclicos/química , Isotiocianatos/química , Cintigrafía/métodos , Albúminas/administración & dosificación , Animales , Neoplasias de la Mama/patología , Neoplasias de la Mama/cirugía , Femenino , Compuestos Heterocíclicos/administración & dosificación , Compuestos Heterocíclicos/farmacología , Isotiocianatos/administración & dosificación , Isotiocianatos/farmacología , Microesferas , Radiofármacos , Ratas , Biopsia del Ganglio Linfático Centinela/métodos , Cirugía Asistida por Computador/métodos , Agregado de Albúmina Marcado con Tecnecio Tc 99m/administración & dosificación , Agregado de Albúmina Marcado con Tecnecio Tc 99m/química , Agregado de Albúmina Marcado con Tecnecio Tc 99m/farmacología
4.
Curr Radiopharm ; 12(2): 107-125, 2019.
Artículo en Inglés | MEDLINE | ID: mdl-30843499

RESUMEN

BACKGROUND: Neuroendocrine Tumors (NETs) are relatively rare tumors, mainly originating from the digestive system, that tend to grow slowly and are often diagnosed when metastasised. Surgery is the sole curative option but is feasible only in a minority of patients. Among them, pancreatic neuroendocrine tumors (pancreatic NETs or pNETs) account for less than 5% of all pancreatic tumors. Viable therapeutic options include medical treatments such as biotherapies and more recently Peptide Receptor Radionuclide Therapies (PRRT) with radiolabeled somatostatin analogues. Molecular imaging, with main reference to PET/CT, has a major role in patients with pNETs. OBJECTIVE: The overexpression of specific membrane receptors, as well as the ability of cells to take up amine precursors in NET, have been exploited for the development of specific targeting imaging agents. METHODS: SPECT/CT and PET/CT with specific isotopes such as [68Ga]-1,4,7,10-tetra-azacyclododecane- N,N',N'',N'''-tetra-acetic acid (DOTA)-somatostatin analogs, [18F]-FDG and [18F]-fluorodopa have been clinically explored. RESULTS: To overcome the limitations of SSTR imaging, interesting improvements are connected with the availability of new radiotracers, activating with different mechanisms compared to somatostatin analogues, such as glucagon-like peptide 1 receptor (GLP-1 R) agonists or antagonists. CONCLUSION: This paper shows an overview of the RPs used so far in the imaging of pNETs with insight on potential new radiopharmaceuticals currently under clinical evaluation.


Asunto(s)
Tumores Neuroendocrinos/diagnóstico por imagen , Neoplasias Pancreáticas/diagnóstico por imagen , Radiofármacos/farmacología , Aminas , Tumor Carcinoide/diagnóstico por imagen , Diferenciación Celular , Humanos , Radioisótopos de Indio , Islotes Pancreáticos/patología , Tomografía Computarizada por Tomografía de Emisión de Positrones/tendencias , Receptores de Somatostatina/metabolismo , Tomografía Computarizada de Emisión de Fotón Único
5.
Curr Radiopharm ; 9(1): 19-32, 2016.
Artículo en Inglés | MEDLINE | ID: mdl-25771368

RESUMEN

Peptide receptor radionuclide therapy (PRRT) using radiolabeled somatostatin analogues has shown encouraging results in various somatostatin receptor positive tumors. Partial remission rates up to 30% have been documented as well as significant improvements in quality of life and survival. This treatment takes advantage of the high specific binding of the radiolabeled peptide to somatostatin receptors overexpressed by the tumors thus being more effective on the tumor cells with less systemic side-effects. The development of macrocyclic chelators conjugated to peptides made possible the stable binding with various radionuclides. In particular 177Lu features favourable physical characteristics with a half-life of 6.7 days, emission of ß- with energy of 0.5 MeV for treatment and γ-emissions suitable for imaging. The present contribution describes the learning process achieved at the European Institute of Oncology (IEO) since the first application of 90Y labeled peptides to the therapy of neuroendocrine tumors back in 1997. Continuous improvements led to the preparation of a safe 177Lu labeled peptide for human use. Our learning curve began with the identification of the optimal characteristics of the isotope paying attention to its chemical purity and specific activity along with the optimization of the parameters involved in the radiolabeling procedure. Also the radiation protection issues have been improved along the years and recently more and more attention has been devoted to the pharmaceutical aspects involved in the preparation. The overall issue of the quality has now been completed by drafting an extensive documentation with the goal to deliver a safe and reliable product to our patients.


Asunto(s)
Lutecio/administración & dosificación , Tumores Neuroendocrinos/radioterapia , Radiofármacos/administración & dosificación , Somatostatina/administración & dosificación , Química Farmacéutica/métodos , Humanos , Lutecio/efectos adversos , Péptidos/administración & dosificación , Péptidos/efectos adversos , Calidad de Vida , Radioisótopos/administración & dosificación , Radioisótopos/efectos adversos , Radiofármacos/efectos adversos , Receptores de Péptidos/metabolismo , Receptores de Somatostatina/metabolismo , Somatostatina/efectos adversos , Somatostatina/análogos & derivados
6.
Org Biomol Chem ; 13(13): 3988-4001, 2015 Apr 07.
Artículo en Inglés | MEDLINE | ID: mdl-25722026

RESUMEN

Chemical modifications of the biotin carrier in pretargeted avidin­biotin radionuclide therapy may be of paramount importance for tuning the amount of the radioactivity delivered to cancer cells by labelled biotins. We report here the synthesis of a collection of new synthetic DOTA-constructs bearing two (+)-biotin molecules (bis-biotins), designed for the creation of multimeric Av units (tetramers) bonded to the antibody. All the syntheses were carried out following the solid phase strategy and growing the molecules on a Rink Amide resin. The biotin heads are connected through spacers containing PEG or non-PEG residues. Molecular modelling calculations suggested that the Av cross-linking ability of the bis-biotins depends mainly on the spacers length, with the best results being expected for arms affording distances in the range of 10­25 Å between the biotin carboxylate atoms, in the fully extended conformation. SEC-HPLC MALLS analysis of the products of our Av/bis-biotin reaction mixtures have confirmed this hypothesis. The bis-biotin 16, where the non-PEG linker ensured a distance of 26.7 Å between the biotin moieties, gave about 50% of Av oligomers while the shorter analogue 18 (19.5 Å) afforded 100% of an Av polymer containing about 21 protein units. Remarkably, the solubility of both the bis-biotins, i.e.16 and 18, in aqueous solutions was good and they showed excellent stability against the action of peptidases.


Asunto(s)
Avidina/química , Biotina/química , Biotina/síntesis química , Dimerización , Diseño de Fármacos , Compuestos Heterocíclicos con 1 Anillo/química , Multimerización de Proteína , Estabilidad de Medicamentos , Marcaje Isotópico , Modelos Moleculares , Peso Molecular , Estructura Cuaternaria de Proteína , Técnicas de Síntesis en Fase Sólida
7.
Nucl Med Commun ; 34(3): 265-70, 2013 Mar.
Artículo en Inglés | MEDLINE | ID: mdl-23276826

RESUMEN

The aim of this paper was to describe the optimized labeling protocol and quality control measures used in the production of [(90)Y]DOTATOC, starting from three different radioactivity levels to treat one, two, or three patients per therapeutic session. We investigated three different starting radioactivity levels. For the low radioactivity preparation we used 5138±280 MBq of [Y] isotope, for the medium radioactivity preparation we used 8893±900 MBq, and for the high radioactivity preparation we used 11250±715 MBq. The radiochemical purity levels for the low radioactivity preparation, medium radioactivity preparation, and high radioactivity preparation were 99.95±0.09, 99.84±0.34, and 99.84±0.53%, respectively, and the radiochemical yields of the labeling procedures were 77.52±1.28, 75.53±3.72, and 78.00±3.20%, respectively. Media fill validation of the process was performed, and the parameters of pH, bacterial endotoxins, sterility, and osmolality were tested at process control. All radiopharmaceutical preparations satisfied the predetermined specifications fixed in our protocol regardless of the starting radioactivity level. The validation of the method guaranteed the safety and quality of the final products, contributing to providing the basis for constructing an informative and successful clinical trial.


Asunto(s)
Tumores Neuroendocrinos/tratamiento farmacológico , Tumores Neuroendocrinos/radioterapia , Octreótido/análogos & derivados , Bacterias/metabolismo , Química Farmacéutica/métodos , Endotoxinas/metabolismo , Neoplasias Gastrointestinales/tratamiento farmacológico , Neoplasias Gastrointestinales/radioterapia , Humanos , Concentración de Iones de Hidrógeno , Metástasis de la Neoplasia , Octreótido/química , Octreótido/farmacología , Concentración Osmolar , Control de Calidad , Reproducibilidad de los Resultados
8.
Eur J Nucl Med Mol Imaging ; 39 Suppl 1: S93-102, 2012 Feb.
Artículo en Inglés | MEDLINE | ID: mdl-22388625

RESUMEN

Peptide receptor radionuclide therapy (PRRT) consists in the systemic administration of a synthetic peptide, labelled with a suitable beta-emitting radionuclide, able to irradiate tumours and their metastases via the internalization through a specific receptor, overexpressed on the cell membrane. After 15 years of experience, we can state that PRRT with (90)Y-labelled peptides is generally well tolerated. Acute side effects are usually mild, some of which are related to the co-administration of amino acids, such as nausea. Others are related to the radiopeptide, such as fatigue or the exacerbation of an endocrine syndrome, which rarely occurs in functioning tumours. Chronic and permanent effects on target organs, particularly the kidneys and the bone marrow, are generally mild if the necessary precautions are taken. Currently, the potential risk to kidney and red marrow limits the amount of radioactivity that may be administered. However, when tumour masses are irradiated with adequate doses, volume reduction may be observed. (90)Y-octreotide has been the most widely used radiopeptide in the first 8-10 years of experience. Unfortunately, all of the published results derive from different and inhomogeneous phase I/II studies. Hence, a direct comparison is virtually impossible to date. Nevertheless, even with these limitations, objective responses are registered in 10-34% of patients. The optimal timing of (90)Y-DOTATOC in the management of somatostatin receptor (SSTR)-positive tumours and the way in which it should be integrated with other treatments have yet to be defined, and prospective phase II/III trials comparing the efficacy and toxicity of different schemes of (90)Y-DOTATOC administration are still warranted.


Asunto(s)
Tumores Neuroendocrinos/radioterapia , Péptidos/uso terapéutico , Radiofármacos/uso terapéutico , Radioisótopos de Itrio/uso terapéutico , Médula Ósea/efectos de la radiación , Ensayos Clínicos como Asunto , Humanos , Riñón/metabolismo , Riñón/efectos de la radiación , Lutecio/uso terapéutico , Tumores Neuroendocrinos/metabolismo , Octreótido/efectos adversos , Octreótido/análogos & derivados , Octreótido/uso terapéutico , Radioisótopos/uso terapéutico , Radiofármacos/efectos adversos , Dosificación Radioterapéutica , Receptores de Péptidos/metabolismo , Seguridad , Resultado del Tratamiento , Radioisótopos de Itrio/efectos adversos
9.
Eur J Nucl Med Mol Imaging ; 38(12): 2125-35, 2011 Dec.
Artículo en Inglés | MEDLINE | ID: mdl-21892623

RESUMEN

PURPOSE: Peptide receptor radionuclide therapy (PRRT) is used in tumours expressing type 2 somatostatin receptors (sst(2)), mainly neuroendocrine. The aim of this prospective phase I-II study was to evaluate the toxicity and efficacy of (177)Lu-DOTATATE in multiple cycles. METHODS: Fifty-one consecutive patients with unresectable/metastatic sst(2)-positive tumours, divided into two groups, received escalating activities (3.7-5.18 GBq/cycle, group 1; 5.18-7.4 GBq/cycle, group 2) of (177)Lu-DOTATATE. Cumulative activities ranged from 3.7 to 29.2 GBq (median 26.4 GBq in median 6 cycles, group 1, 21 patients) and 5.55 to 28.9 GBq (median 25.2 GBq in 4 cycles, group 2, 30 patients), based on dosimetry. RESULTS: No major acute or delayed renal or haematological toxicity occurred (one grade 3 leukopenia and thrombocytopenia). Cumulative renal absorbed doses were 8-37 Gy (9-41 Gy bioeffective doses). A median decrease of creatinine clearance of 21.7% 6 months after PRRT, 23.9% after 1 year and 27.6% after 2 years was observed. Higher losses (>20%) occurred in patients with risk factors for renal toxicity, particularly hypertension and diabetes. Cumulative bone marrow doses were <1.5 Gy. Blood elements showed a progressive mild drop during cycles and recovered during follow-up (median 30 months). Thirty-nine patients were progressive at enrolment. Partial and complete responses occurred in 15 of 46 (32.6%) assessable patients. The median time to progression was 36 months. Overall survival was 68% at 36 months. Non-responders and patients with extensive tumour involvement had lower survival. CONCLUSION: (177)Lu-DOTATATE was well tolerated up to 29 GBq cumulative activity (up to 7.4 GBq/cycle). The maximum tolerated dose/cycle was not reached. However, considering the individual bone marrow function and the presence of risk factors for kidney toxicity, it seems safer to divide cumulative activities into lower activity cycles.


Asunto(s)
Enfermedades Renales/etiología , Tumores Neuroendocrinos/metabolismo , Tumores Neuroendocrinos/radioterapia , Octreótido/análogos & derivados , Compuestos Organometálicos/efectos adversos , Compuestos Organometálicos/uso terapéutico , Traumatismos por Radiación/etiología , Receptores de Somatostatina/metabolismo , Adulto , Anciano , Relación Dosis-Respuesta en la Radiación , Femenino , Humanos , Enfermedades Renales/diagnóstico , Masculino , Dosis Máxima Tolerada , Persona de Mediana Edad , Tumores Neuroendocrinos/diagnóstico , Octreótido/efectos adversos , Octreótido/farmacocinética , Octreótido/uso terapéutico , Compuestos Organometálicos/farmacocinética , Traumatismos por Radiación/diagnóstico , Radiofármacos/efectos adversos , Radiofármacos/farmacología , Radiofármacos/uso terapéutico , Resultado del Tratamiento
10.
Cancer Biother Radiopharm ; 26(3): 287-97, 2011 Jun.
Artículo en Inglés | MEDLINE | ID: mdl-21711096

RESUMEN

BACKGROUND: The humanized monoclonal antibody Nimotuzumab (h-R3) has demonstrated an exceptional and better clinical profile than other monoclonal antibodies for immunotherapy of epidermal growth factor receptor-overexpressing tumors. This work deals with the preparation and radiolabeling optimization of (177)Lu-Nimotuzumab and their preclinical evaluation. METHODS: Nimotuzumab was conjugated with S-2-(4-isothiocyanatobenzyl)-1,4,7,10-tetraazacyclododecane tetraacetic acid (p-SCN-Bn-DOTA), testing different molar ratios. The immunoconjugates were characterized. The radiolabeling with (177)Lu was optimized. Radioimmunoconjugates stability was tested in 2-[bis[2-[bis(carboxymethyl)amino]ethyl]amino]acetic acid (DTPA) excess and human serum. In vitro studies were performed in tumor model cell lines. Receptor-specific binding was tested by competitive inhibition. (177)Lu-Nimotuzumab in vivo studies were conducted in healthy and xenograft animals. RESULTS: Nimotuzumab conjugates were obtained with high purity. Radiolabeling yield and specific activities ranged from 63.6% to 94.5% and from 748 to 1142 MBq/mg, respectively. The stability in DTPA excess and human serum was 95.9% and 93.2% after 10 days, respectively. The radioimmunoconjugate showed specific receptor binding in tumor cell lines. Biodistribution in healthy animals showed the typical behavior of the immunoconjugates based on monoclonal antibodies. The study in xenografts mice demonstrated uptake of (177)Lu-Nimotuzumab in the tumor and reticuloendothelial organs. CONCLUSIONS: (177)Lu-Nimotuzumab was obtained with high purity and specific activities under optimal conditions without significant loss in immunoreactivity and might be a potential radioimmunoconjugate for radioimmunotherapy of tumors with epidermal growth factor receptor overexpression.


Asunto(s)
Anticuerpos Monoclonales Humanizados/uso terapéutico , Receptores ErbB/biosíntesis , Regulación Neoplásica de la Expresión Génica , Inmunoconjugados/uso terapéutico , Lutecio/uso terapéutico , Neoplasias/terapia , Radioinmunoterapia/métodos , Radioisótopos/uso terapéutico , Animales , Línea Celular Tumoral , Quelantes/farmacología , Cromatografía Líquida de Alta Presión/métodos , Femenino , Compuestos Heterocíclicos/farmacología , Humanos , Isotiocianatos/farmacología , Ratones , Trasplante de Neoplasias , Ratas , Ratas Wistar , Factores de Tiempo
11.
Cancer Biother Radiopharm ; 25(2): 143-8, 2010 Apr.
Artículo en Inglés | MEDLINE | ID: mdl-20423226

RESUMEN

Avidin is widely used in vitro for its capacity to bind biotin. However, avidin's in vivo use is limited by its short residence in blood and tissues. An avidin variant, named AvidinOX, has been recently described. This product is obtained by 4-hydroxyazobenzene-2'-carboxylic acid-assisted sodium periodate oxidation of avidin. This method generates aldehyde groups from avidin carbohydrates, sparing biotin-binding sites from inactivation. AvidinOX binds cellular and interstitial protein amino groups through Schiff's bases, resulting in a tissue half-life of 2 weeks, compared with 2 hours of native avidin. Binding of AvidinOX occurs in normal and neoplastic tissues. Data show that AvidinOX, administered intranipple in the breast of transgenic BALB/neuT mice, is highly efficient for capturing (90)Y-biotinDOTA, intravenously injected after 48 hours, leading to eradication of multifocal cancer lesions. Efficacy data, together with good tolerability results, indicate that AvidinOX is a highly innovative reagent for tissue-pretargeted radionuclide therapy.


Asunto(s)
Avidina/administración & dosificación , Tratamiento Basado en Trasplante de Células y Tejidos , Neoplasias Mamarias Experimentales/radioterapia , Radioisótopos de Itrio/uso terapéutico , Animales , Estudios de Factibilidad , Femenino , Humanos , Neoplasias Mamarias Experimentales/metabolismo , Ratones , Ratones Endogámicos BALB C , Ratones Transgénicos , Oxidación-Reducción , Distribución Tisular , Resultado del Tratamiento
12.
Nucl Med Biol ; 37(1): 85-93, 2010 Jan.
Artículo en Inglés | MEDLINE | ID: mdl-20122673

RESUMEN

INTRODUCTION: (90)Y-Zevalin labeling may cause severe finger radiation exposure, especially in high-dose protocols (HD-Zevalin), where up to 7.4 GBq could be injected. In this work, we optimized the labeling of HD-Zevalin with special regard to simplicity, speed, safety and radiation protection. METHODS: Factors influencing labeling outcome (activity, specific activity, time, final volume, stability) were studied separately. The critical steps of a standard radiolabeling procedure were optimized to reduce finger exposure, developing an alternative labeling procedure and including a different (90)Y supplier. Finger doses were monitored by thermoluminescent dosimeters at each fingertip under anti-X gloves, considering both absolute values and values after normalization to 1.48 GBq. RESULTS: Labeling of (90)Y-Zevalin was safe and reproducible up to 7.4 GBq with a simple and single-step procedure offering good stability for several hours. Radiolabeling specific activity was found critical, being kept at 740 MBq mg(-1). Radiochemical purity values >or=98% were routinely achieved. The alternative procedure allowed a sensible reduction of finger dose, due to both the different (90)Y vial and the handling. Finger exposure was reduced from 6.6+/-4.3 to 3.1+/-0.8 mSv/1.48 GBq in the case of the original (90)Y vial and from 1.5+/-0.9 to 0.3+/-0.1 mSv/1.48 GBq using a shielded (90)Y vial. CONCLUSIONS: HD-Zevalin can be prepared in a safe and reproducible way, giving high radiochemical purity values, good stability and low finger exposure. This study may improve the safety of nuclear medicine professionals involved in the preparation of Zevalin.


Asunto(s)
Anticuerpos Monoclonales , Marcaje Isotópico/métodos , Exposición Profesional , Dosis de Radiación , Anticuerpos Monoclonales/administración & dosificación , Dedos/efectos de la radiación , Humanos , Marcaje Isotópico/normas , Control de Calidad , Radiofármacos/administración & dosificación , Seguridad
13.
J Med Chem ; 53(1): 432-40, 2010 Jan 14.
Artículo en Inglés | MEDLINE | ID: mdl-19928962

RESUMEN

The synthesis of four biotin derivatives carrying two DOTA moieties for each ligand (BisDOTA set) is reported, for increasing radiation/dose ratio and improving efficiency in the pretargeted avidin-biotin radioimmunotherapy. The biotin-containing scaffold of two BisDOTA was similar to the mono-DOTA derivative previously described. Then the scaffold was elongated by trifunctionalized spacers of different length and conjugated with one of the COOH groups of two DOTA. Two others were prepared starting from a on-resin lysine residue. The lysine alpha-NH2 was bonded to biotin, and then spacers were appended to the epsilon-NH2 and conjugated with two DOTA molecules. One compound contained a p-aminobenzoic acid spacer, which ensured higher head-to-tail distance and increased rigidity of the chain. These last two compounds had a very high ability to bond avidin and were labeled with 90Y at high specific activity. All the compounds were resistant to the action of serum biotinidases.


Asunto(s)
Avidina/química , Biotina/análogos & derivados , Quelantes/química , Compuestos Organometálicos/síntesis química , Compuestos Organometálicos/farmacología , Animales , Sitios de Unión , Biotina/síntesis química , Biotina/química , Biotina/farmacología , Marcaje Isotópico , Ratones , Estructura Molecular , Compuestos Organometálicos/química
14.
Appl Radiat Isot ; 67(10): 1874-7, 2009 Oct.
Artículo en Inglés | MEDLINE | ID: mdl-19628401

RESUMEN

(90)Y is one of the most useful radionuclides for radioimmunotherapeutic applications and has a half-life (t(1/2)=64.14h) suitable for most therapeutic applications, beta particles of high energy and decays to a stable daughter. It is significant that (90)Y is available conveniently and inexpensively from a radionuclide "generator" by decay of its parent, (90)Sr. Nevertheless, current and planned clinical applications with [(90)Y] labelled compounds employ activity levels that cannot be readily obtained from an in-house generator, but from commercial sources. We have evaluated Eichrom's Sr-resin, either as an "in-house" generator or as a fast QC method for analysis of (90)Y solutions. In particular, for the development as a generator, we investigated the percentage of the radio-Sr in the first 8M HNO(3) eluate: in this fraction the concentration of (90)Sr must be smaller than 10(-5)% (recommendations of the International Commission on Radiological Protection). For evaluation as a rapid QC method, we analyzed the concentration of (90)Y in all the fractions containing "only" radio-Sr: (90)Y should not be present in these eluates. After the collection of beta(-) and gamma spectra and analysis of them, we concluded that commercial Sr-resin minicolumn cannot give us the results expected; we developed an in-house system loaded with 4mL of Sr-resin which gave better results as a generator and a rapid QC method.


Asunto(s)
Radiofármacos/síntesis química , Radioisótopos de Estroncio/análisis , Radioisótopos de Itrio , Cromatografía por Intercambio Iónico , Marcaje Isotópico/métodos , Radioisótopos/química
15.
Br J Haematol ; 139(4): 590-9, 2007 Nov.
Artículo en Inglés | MEDLINE | ID: mdl-17979944

RESUMEN

Radioimmunotherapy (RIT) is an alternative approach in the treatment of resistant/refractory B-cell non-Hodgkin lymphoma (NHL). We performed a feasibility and toxicity pilot study of escalating activity of 90Y-ibritumomab tiuxetan followed by autologous stem cell transplantation (ASCT). Three activity levels were fixed--30 MBq/kg (0.8 mCi/kg), 45 MBq/kg (1.2 mCi/kg) and 56 MBq/kg (1.5 mCi/kg)--and 13 patients enrolled. One week before treatment all patients underwent dosimetry. ASCT was performed 13 d after Zevalin administration. Treatment was well tolerated and all patients engrafted promptly. No differences in terms of haematological toxicities were observed among the three levels, apart from a delayed platelet recovery in heavily pretreated patients receiving 56 MBq/kg. Non-haematologic toxicity was mainly related to infections and liver toxicity. One patient died 4 months after treatment because of hepatitis C virus reactivation. One patient developed a myelodysplastic syndrome 2 years after treatment. In conclusion, high-activity Zevalin with ASCT is feasible and could be safely delivered in elderly and heavily pretreated NHL patients, including those who previously received high-dose chemotherapy and ASCT. Maximum tolerated dose was not clearly defined according to dosimetry and clinical toxicities, and further studies are needed to confirm the toxicity profile and evaluate efficacy.


Asunto(s)
Anticuerpos Monoclonales/uso terapéutico , Linfoma de Células B/terapia , Trasplante de Células Madre de Sangre Periférica/métodos , Radioinmunoterapia/métodos , Adulto , Anciano , Anticuerpos Monoclonales/efectos adversos , Terapia Combinada , Resistencia a Antineoplásicos , Estudios de Factibilidad , Femenino , Supervivencia de Injerto , Humanos , Linfoma de Células B/radioterapia , Masculino , Persona de Mediana Edad , Proyectos Piloto , Radioinmunoterapia/efectos adversos , Dosificación Radioterapéutica , Recurrencia , Resultado del Tratamiento
16.
Clin Cancer Res ; 13(18 Pt 2): 5646s-5651s, 2007 Sep 15.
Artículo en Inglés | MEDLINE | ID: mdl-17875802

RESUMEN

PURPOSE: In a continuous effort to seek for anticancer treatments with minimal side effects, we aim at proving the feasibility of the Intraoperative Avidination for Radionuclide Therapy, a new procedure for partial breast irradiation. EXPERIMENTAL DESIGN: To assess doses of 90Y-DOTA-biotin to target (i.e., breast tumor bed) and nontarget organs, we did simulation studies with 111In-DOTA-biotin in 10 candidates for conservative breast surgery. Immediately after quadrantectomy, patients were injected with 100-mg avidin in the tumor bed. On the following day, patients were given 111In-DOTA-biotin (approximately 111 MBq) i.v. after appropriate chase of biotinylated albumin (20 mg) to remove circulating avidin. Biokinetic studies were done by measuring radioactivity in scheduled blood samples, 48-h urine collection, and through scintigraphic images. The medical internal radiation dose formalism (OLINDA code) enabled dosimetry assessment in target and nontarget organs. RESULTS: Images showed early and long-lasting radioactive biotin uptake in the operated breast. Rapid blood clearance (<1% at 12 h) and urine excretion (>75% at 24 h) were observed. Absorbed doses, expressed as mean+/-SD in Gy/GBq, were as low as 0.15+/-0.05 in lungs, 0.10+/-0.02 in heart, 0.06+/-0.02 in red marrow, 1.30+/-0.50 in kidneys, 1.50+/-0.30 in urinary bladder, and 0.06+/-0.02 in total body, whereas in the targeted area, they increased to 5.5+/-1.1 Gy/GBq (50% ISOROI) and 4.8+/-1.0 Gy/GBq (30% ISOROI). CONCLUSION: Our preliminary results suggest that Intraoperative Avidination for Radionuclide Therapy is a simple and feasible procedure that may improve breast cancer patients' postsurgical management by shortening radiotherapy duration.


Asunto(s)
Avidina/administración & dosificación , Biotina/análogos & derivados , Braquiterapia/métodos , Neoplasias de la Mama/diagnóstico por imagen , Neoplasias de la Mama/radioterapia , Compuestos Organometálicos/administración & dosificación , Adolescente , Adulto , Anciano , Avidina/farmacocinética , Biotina/administración & dosificación , Biotina/farmacocinética , Neoplasias de la Mama/cirugía , Terapia Combinada , Femenino , Humanos , Radioisótopos de Indio , Inyecciones Intralesiones , Inyecciones Intravenosas , Periodo Intraoperatorio , Mastectomía Segmentaria , Persona de Mediana Edad , Compuestos Organometálicos/farmacocinética , Proyectos Piloto , Estudios Prospectivos , Cintigrafía , Radiofármacos , Radioterapia Adyuvante , Biopsia del Ganglio Linfático Centinela , Distribución Tisular , Radioisótopos de Itrio
17.
Eur J Nucl Med Mol Imaging ; 34(1): 68-77, 2007 Jan.
Artículo en Inglés | MEDLINE | ID: mdl-16755333

RESUMEN

PURPOSE: A novel biotin-DOTA conjugate (r-BHD: reduced biotinamidohexylamine-DOTA) was investigated in order to provide an efficient pretargeted antibody-guided radioimmunotherapy (PAGRIT) application. Preclinical and clinical results are described. METHODS: (90)Y and (177)Lu were used to label r-BHD. The effect of pH and a wide range of specific activities were studied. Radiolabelled r-BHD was tested for affinity towards avidin and for stability in saline or in human serum with and without ascorbic acid. Pharmacokinetic data were collected and organ biodistribution evaluated in a tumour-bearing pretargeted animal model. A pilot study was performed in a metastatic melanoma patient and dosimetry was estimated. RESULTS: High radiochemical purity (>99%) was routinely achieved with (90)Y or (177)Lu in sodium acetate buffer (1.0 M, pH 5.0) at a specific activity of 2.6 MBq/nmol. Both (90)Y- and (177)Lu-r-BHD were also prepared at higher specific activities. Radiolabelled r-BHD was stable up to 96 h in human serum and saline with the addition of ascorbic acid. The structural modifications proposed for the r-BHD stabilised it against enzymatic degradation while retaining high binding affinity for avidin. Renal clearance appeared to be the main route of excretion in animals, and high tumour uptake was observed in the pretargeted animals. The patient study showed a total body clearance of approximately 85% in 24 h, with a kidney absorbed dose of 1.5 mGy/MBq. Tumour uptake was rapid and the calculated dose to a 10-mm tumour lesion was approximately 12 mGy/MBq. CONCLUSION: These results indicate that the new biotin-DOTA conjugate may be a suitable candidate for pretargeting trials.


Asunto(s)
Biotina/farmacocinética , Compuestos Heterocíclicos con 1 Anillo/farmacocinética , Radioisótopos/farmacocinética , Radiofármacos/farmacocinética , Animales , Anticuerpos Monoclonales/farmacocinética , Anticuerpos Monoclonales/uso terapéutico , Biotina/química , Biotina/uso terapéutico , Sistemas de Liberación de Medicamentos/métodos , Evaluación Preclínica de Medicamentos , Compuestos Heterocíclicos con 1 Anillo/química , Compuestos Heterocíclicos con 1 Anillo/uso terapéutico , Marcaje Isotópico/métodos , Masculino , Tasa de Depuración Metabólica , Ratones , Ratones Endogámicos C57BL , Especificidad de Órganos , Radioinmunoterapia/métodos , Radioisótopos/química , Radioisótopos/uso terapéutico , Radiofármacos/síntesis química , Radiofármacos/uso terapéutico , Distribución Tisular
18.
Neurol Res ; 28(5): 518-22, 2006 Jul.
Artículo en Inglés | MEDLINE | ID: mdl-16808882

RESUMEN

Despite years of intensive research, the prognosis of high-grade gliomas (HGG) remains poor, as these tumors are highly resistant to currently available therapies. Therefore, there is a need for the development of new therapeutic strategies, such as the use of monoclonal antibodies (MoAbs) in association with radioisotopes, in order to achieve better responses and prognosis. This article describes our experience in radioimmunotherapy (RIT) with MoAbs and tumor pre-targeting with the avidin-biotin system, either in systemic or locoregional administrations. This therapy offers the exciting prospect of increasing the specificity of tumor cell irradiation with radioisotopes. We suggest that RIT, both systemic and locoregional, should be used as part of a combined modality approach: in combination with surgery, radiotherapy and chemotherapy.


Asunto(s)
Neoplasias Encefálicas/radioterapia , Glioblastoma/terapia , Radioinmunoterapia , Animales , Anticuerpos Monoclonales/uso terapéutico , Antineoplásicos/uso terapéutico , Neoplasias Encefálicas/tratamiento farmacológico , Ensayos Clínicos como Asunto , Terapia Combinada , Humanos , Radioinmunoterapia/métodos , Radioinmunoterapia/tendencias
19.
Eur J Nucl Med Mol Imaging ; 33(11): 1321-7, 2006 Nov.
Artículo en Inglés | MEDLINE | ID: mdl-16832636

RESUMEN

PURPOSE: The widespread interest in (90)Y internal radionuclide treatments has drawn attention to the issue of radiation protection for staff. Our aim in this study was to identify personnel at risk and to validate the protection devices used. METHODS: (90)Y-MoAb (Zevalin, 15 cases, 1.1 GBq/patient) and (90)Y-peptide ((90)Y-DOTATOC) systemic (i.v., 50 cases, 3.0 GBq/patient) and locoregional (l.r., 50 cases, 0.4 GBq/patient) treatments were considered. Radiolabelling was carried out in a dedicated hot cell. Tele-tongs, shielded (PMMA: polymethylmethacrylate) syringes/vials and an automatic dose fractionating system were used. Operators wore anti-X-ray and anti-contamination gloves, with TLD dosimeters placed over the fingertips. For i.v. administration, activity was administered by a dedicated system; for l.r. administration, during activity infusion in the brain cavity, tongs were used and TLDs were placed over the fingertips. The air kerma-rate was measured around the patients. RESULTS: The use of devices provided a 75% dose reduction, with mean fingertip doses of 2.9 mGy (i.v. MoAbs), 0.6 mGy (i.v. peptides)/radiolabelling procedure and 0.5 mGy/l.r. administration. The mean effective dose to personnel was 5 microSv/patient. The air kerma-rate around the patients administered i.v. (90)Y-peptides were 3.5 (1 h) and 1.0 (48 h) microGy/h at 1 m. Patient hospitalisation of 6 h (l.r.)/48 h (i.v.) guaranteed that the recommended limits of 3 mSv/year to family members and 0.3 mSv/year to the general population (Council Directive 97/43/Euratom) were respected. CONCLUSIONS: When specific procedures are adopted, a substantial improvement in (90)Y manipulation is attainable, reducing doses and increasing safety. For the widespread clinical use of (90)Y-conjugates, a completely automatic labelling procedure is desirable.


Asunto(s)
Cuerpo Médico de Hospitales , Exposición Profesional/análisis , Protección Radiológica/instrumentación , Protección Radiológica/métodos , Medición de Riesgo/métodos , Radioisótopos de Itrio/análisis , Radioisótopos de Itrio/uso terapéutico , Italia , Salud Laboral , Dosis de Radiación , Monitoreo de Radiación/instrumentación , Monitoreo de Radiación/métodos , Radiofármacos/análisis , Radiofármacos/uso terapéutico , Factores de Riesgo
20.
Clin Cancer Res ; 12(7 Pt 1): 2191-6, 2006 Apr 01.
Artículo en Inglés | MEDLINE | ID: mdl-16609034

RESUMEN

ST2146biot is a biotinylated anti-tenascin monoclonal antibody (mAb) to be used for Pretargeted Antibody Guided Radioimmunotherapy (PAGRIT) of solid tumors. In vivo biodistribution studies of (125)I-labeled ST2146biot were done in nude mice transplanted with human HT-29 colon carcinoma and/or human U-118MG glioblastoma cells characterized for low and high tenascin expression, respectively. In vitro results show that ST2146 retains immunoreactivity upon biotinylation, in contrast to other anti-tenascin mAbs. In vivo biodistribution of ST2146 shows specific tumor accumulation up to 10 days after the i.v. injection, with no relevant differences between biotinylated and nonbiotinylated ST2146. A dose of 4 microg/mouse saturates the low tenascin-expressing human colon carcinoma HT-29, whereas the high tenascin-expressing human glioblastoma U-118MG seems to be saturated at a ST2146biot dose between 320 and 640 microg/mouse. The percentage of injected dose per gram of tumor ranges from 10% to 30%, corresponding to an amount of ST2146biot/g of tumor of approximately 400 ng/g and >200 microg/g for HT-29 and U-118MG, respectively. Tumor to normal organs uptake ratios are between 15 and 60, confirming high tumor selectivity of ST2146biot despite its cross-reactivity with the tenascin expressed at low level in the normal mouse organs. The ST2146biot localization data are substantially confirmed even when both low and high tenascin-expressing tumors are implanted in the same animal. To our knowledge, the absolute amount of ST2146biot, specifically localized in xenotransplanted human tumors, is the highest thus far described and supports the clinical use of this mAb in PAGRIT(R).


Asunto(s)
Adenocarcinoma/metabolismo , Anticuerpos Monoclonales/farmacocinética , Especificidad de Anticuerpos , Neoplasias de la Mama/metabolismo , Neoplasias del Colon/metabolismo , Glioblastoma/metabolismo , Tenascina/inmunología , Adenocarcinoma/inmunología , Adenocarcinoma/patología , Animales , Anticuerpos Monoclonales/química , Biotinilación , Neoplasias de la Mama/inmunología , Neoplasias de la Mama/patología , Línea Celular Tumoral , Neoplasias del Colon/inmunología , Neoplasias del Colon/patología , Modelos Animales de Enfermedad , Ensayos de Selección de Medicamentos Antitumorales , Glioblastoma/inmunología , Glioblastoma/patología , Humanos , Técnicas In Vitro , Ratones , Ratones Endogámicos BALB C , Ratones Desnudos , Trasplante de Neoplasias , Radioinmunoterapia/métodos , Relación Estructura-Actividad , Tenascina/biosíntesis , Trasplante Heterólogo , Ensayos Antitumor por Modelo de Xenoinjerto
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA